Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coptisine is a natural protoberberine alkaloid primarily extracted from the medicinal plant *Coptis chinensis* (Rhizoma Coptidis) and *Chelidonium majus*. It is chemically related to berberine and has been extensively studied for its diverse pharmacological activities, including anti-inflammatory, antimicrobial, and antineoplastic properties. Research indicates that coptisine exerts anti-tumor effects by modulating several key intracellular signaling pathways; notably, it has been shown to block the progression of bladder cancer by inhibiting the **PI3K/AKT pathway**, which reduces cell proliferation and induces apoptosis. Beyond oncology, coptisine is investigated for its potential in treating metabolic disorders such as diabetes and hyperlipidemia, often through the activation of **AMP-activated protein kinase (AMPK)**. It also shows inhibitory activity against monoamine oxidase and topoisomerases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on coptisine.